Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- C3G
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- July 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Childrens Hospital Colorado · Aurora, CO
Florida · 1
- Nicklaus Childrens Hospital · Miami, FL
Iowa · 2
- University of Iowa Health Care · Iowa City, IA
- University of Iowa Health Care · Iowa City, IA
Wisconsin · 1
- University of Wisconsin · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.